BioMarin Pharmaceutical (NASDAQ:BMRN) Updates FY 2026 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of 4.850-5.05 for the period, compared to the consensus earnings per share estimate of 4.980. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.7 billion.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Barclays boosted their price objective on BioMarin Pharmaceutical from $80.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. Canaccord Genuity Group boosted their price objective on BioMarin Pharmaceutical from $98.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Bank of America dropped their price objective on BioMarin Pharmaceutical from $97.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Wells Fargo & Company boosted their target price on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Finally, Weiss Ratings raised BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $91.48.

BioMarin Pharmaceutical Stock Up 2.6%

BioMarin Pharmaceutical stock traded up $1.40 during midday trading on Monday, reaching $55.46. The stock had a trading volume of 2,828,047 shares, compared to its average volume of 2,013,607. BioMarin Pharmaceutical has a 12 month low of $50.76 and a 12 month high of $66.28. The company has a market capitalization of $10.72 billion, a P/E ratio of 31.16, a PEG ratio of 0.54 and a beta of 0.23. The company has a fifty day moving average price of $56.93 and a two-hundred day moving average price of $56.32. The company has a current ratio of 5.21, a quick ratio of 3.50 and a debt-to-equity ratio of 0.10.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Monday, May 4th. The biotechnology company reported $0.76 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.18). BioMarin Pharmaceutical had a net margin of 10.83% and a return on equity of 7.91%. The firm had revenue of $766.21 million during the quarter, compared to the consensus estimate of $752.15 million. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.850-5.05 EPS. As a group, equities analysts expect that BioMarin Pharmaceutical will post 4.31 EPS for the current fiscal year.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Gregory R. Friberg sold 6,326 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the completion of the sale, the executive vice president directly owned 37,578 shares of the company’s stock, valued at approximately $2,268,959.64. The trade was a 14.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Charles Greg Guyer sold 16,486 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total value of $996,743.56. Following the sale, the executive vice president directly owned 79,953 shares of the company’s stock, valued at $4,833,958.38. This represents a 17.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.85% of the company’s stock.

Institutional Trading of BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BMRN. Vestal Point Capital LP increased its holdings in BioMarin Pharmaceutical by 261.4% during the 4th quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock worth $178,290,000 after purchasing an additional 2,170,000 shares in the last quarter. Viking Global Investors LP increased its holdings in BioMarin Pharmaceutical by 13.8% during the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after purchasing an additional 1,488,552 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in BioMarin Pharmaceutical by 48.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company’s stock worth $197,405,000 after purchasing an additional 1,076,568 shares in the last quarter. AQR Capital Management LLC increased its holdings in BioMarin Pharmaceutical by 12.7% during the 4th quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company’s stock worth $395,197,000 after purchasing an additional 754,807 shares in the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in BioMarin Pharmaceutical during the 2nd quarter worth approximately $35,202,000. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.